Connect with us

Hi, what are you looking for?

Stock

Novo Nordisk reports 24% sales jump, driven by diabetes and obesity treatments

Investing.com — Novo Nordisk (NYSE:NVO) (CSE:NOVOb) reported strong growth for the first nine months of 2024, with sales jumping by 23% in Danish kroner and 24% at constant exchange rates, reaching DKK 204.7 billion. 

“The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before,” said  president and CEO of Novo Nordisk, Lars Fruergaard Jørgensen, in a statement.

The company’s diabetes and obesity care segment saw a 25% jump in sales, totaling DKK 191.8 billion. 

Within this, obesity care alone rose by an impressive 44%, largely due to Wegovy’s success, which witnessed a 76% surge to DKK 38.3 billion. 

Similarly, diabetes care, supported by GLP-1 products like Ozempic and Rybelsus, also contributed to this increase, particularly in North America, where sales in this segment grew by 31%.

Novo Nordisk’s operating profit showed a comparable upward trend, climbing by 21% in Danish kroner and 22% at CER, reaching DKK 91.6 billion. 

Despite challenges like periodic supply constraints across various markets, the company maintained a strong operating margin of 44.7%, reflecting its successful commercial execution strategies and positive pricing effects. 

In North America, sales were positively influenced by gross-to-net adjustments from previous years, while in international markets, obesity care product uptake further bolstered growth​.

Novo Nordisk also advanced its R&D initiatives, particularly with the SOUL cardiovascular outcomes trial, which confirmed the efficacy of oral semaglutide in reducing major adverse cardiovascular events for diabetes patients. 

In obesity research, the company completed a phase 2a trial for monlunabant and anticipates phase 2b trials in 2025, aiming to expand treatment options for a global patient base.

This post appeared first on investing.com






    You May Also Like

    Editor's Pick

    Sen. JD Vance (R-Ohio) and Minnesota Gov. Tim Walz (D) will face off Tuesday night at a CBS News vice-presidential debate in New York....

    Latest News

    A North Korean defector who escaped to the South more than a decade ago was detained after attempting to cross back into North Korea...

    Economy

    A U.N. human rights group confirmed Hamas’ leader in Lebanon, who was recently killed by Israeli strikes, was their employee.  Fateh Sherif was killed...

    Investing

    Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) have completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands...

    Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 balanceandcharge.com